[18]Nitz U, Gluz O, Graeser M, et al. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 t...
[11]Thuss-Patience PC, Shah MA, Ohtsu A, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Onco...
[18]Nitz U, Gluz O, Graeser M, et al. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 t...
[11]Thuss-Patience PC, Shah MA, Ohtsu A, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international rando...
[14] Snehal Patel, David McWilliams, Jaye Thompson, et al. Baseline GP2 immune response as an independent prognostic factor in a phase IIb study evaluating HER2/neu peptide GP2 (GLSI-100) versus. GM-CSF alone after adjuvant trastuzumab in HER2-posit...
f Kaplan-Meier curve of overall survival (OS) in 761 TCGA tumors with a median follow up of 27 months, divided into five groups based on ER IHC status, PAM50 subtype, and AR activity (positive versus negative AR-ness score). OS was truncated to 12 years of follow up. g Left, ...
[25]Denkert C,et al.Biomarker data from KATHERINE:a phase III study of adjuvant trastuzumab emtansine(T-DM1)versus trastuzumab(H)in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer[abstract].J Clin Oncol 2020;38(15_Suppl):502. ...
associated with worse OS in HER2-positive patients than in HER2-negative patients (Fig.2gand Supplementary Fig.2a). In addition, we also assessed the relationship between SHCBP1 and the clinicopathological characteristics of HER2-positive patients from the gastric cancer TMAs, and found a significant...
[4]Frederik Marme, et al.Sacituzumab govitecan(SG)efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative(HR+/HER2-)metastatic breast cancer(MBC)by HER2 immunohistochemistry(IHC)status in the phase IIITROPiCS-02 study.ESMO 2022,214MO ...
Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer is the most prevalent type of breast cancer, in which endocrine therapy resistance and distant relapse remain unmet challenges. Accurate molecular classification is urgently required for guiding pre...